Shijie Cai
Associate Professor of Experimental Cancer Medicine
- Doctor of Philosophy (PhD) - Gene Therapy, University of Cambridge
- Master of Philosophy (MPhil) - Paediatric Viral Respiratory Infection, University of Liverpool
- Clinical Research Fellow - Paediatric Infectious Diseases, Alder-Hey Children Hospital, University of Liverpool
- Doctor of Medicine - Tongji Medical University, China
Interrogating Tumour–Stromal Crosstalk via Integrated Multi-omics for Biomarker and Target Discovery
Our research aims to understand how tumour cells interact with their surrounding microenvironment. By leveraging integrated multi-omics approaches—including transcriptomics, proteomics, and metabolomics—we analyse data from cell-based models to identify key drivers of tumour development and to determine how they regulate tumour growth and therapy resistance. Our work spans multiple cancer types, including breast, colorectal, cholangiocarcinoma, and pancreatic cancers. By combining insights from laboratory models with patient-derived data, we seek to translate these findings into clinically relevant biomarkers and more effective combination therapies, including targeted therapy and immunotherapy.
Our Team
Medina Abudula - Post-doctoral Research Assistant
Galina Boskh - DPhil
Xinyi Gao - DPhil
Zihe Wang - DPhil (Recognised PhD student)
Amelia Lim - FHS student
Iona Fuhrmann - FHS student
Aling Shen - Academic visitor
Liu Yang - Academic visitor
Key publications
GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner.
Journal article
Wang Z. et al, (2023), Cancer Res, 83, 3400 - 3413
Recent publications
Bestrophin-4 relays HES4 and interacts with TWIST1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells.
Journal article
Wang Z. et al, (2024), Elife, 12
Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Other
Wang Z. et al, (2024)